|
Report Date : |
03.01.2014 |
IDENTIFICATION DETAILS
|
Name : |
BRUKER DALTONICS INC. |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
04.02.2000 |
|
|
|
|
Legal Form : |
Corporation – Profit |
|
|
|
|
Line of Business : |
· Engaged in designing, manufacturing, and marketing of life sciences tools based on mass spectrometry Subject offers matrix assisted laser desorption ionization
time of flight mass spectrometer, electro spray ionization ion trap mass
spectrometer, ultra high resolution time of flight mass spectrometer, fourier
transform mass spectrometer, and mobile detection products. Subject also provides systems for substance detection and
pathogen detection for security, defense, and anti-terrorism applications |
|
|
|
|
No. of Employees : |
600 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
United
States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
united StaTes ECONOMIC OVERVIEW
The US has the largest and most
technologically powerful economy in the world, with a per capita GDP of
$49,800. In this market-oriented economy, private individuals and business firms
make most of the decisions, and the federal and state governments buy needed
goods and services predominantly in the private marketplace. US business firms
enjoy greater flexibility than their counterparts in Western Europe and Japan
in decisions to expand capital plant, to lay off surplus workers, and to
develop new products. At the same time, they face higher barriers to enter
their rivals' home markets than foreign firms face entering US markets. US
firms are at or near the forefront in technological advances, especially in
computers and in medical, aerospace, and military equipment; their advantage
has narrowed since the end of World War II. The onrush of technology largely
explains the gradual development of a "two-tier labor market" in
which those at the bottom lack the education and the professional/technical
skills of those at the top and, more and more, fail to get comparable pay
raises, health insurance coverage, and other benefits. Since 1975, practically
all the gains in household income have gone to the top 20% of households. Since
1996, dividends and capital gains have grown faster than wages or any other
category of after-tax income. Imported oil accounts for nearly 55% of US
consumption. Crude oil prices doubled between 2001 and 2006, the year home
prices peaked; higher gasoline prices ate into consumers' budgets and many
individuals fell behind in their mortgage payments. Oil prices climbed another
50% between 2006 and 2008, and bank foreclosures more than doubled in the same
period. Besides dampening the housing market, soaring oil prices caused a drop
in the value of the dollar and a deterioration in the US merchandise trade
deficit, which peaked at $840 billion in 2008. The sub-prime mortgage crisis,
falling home prices, investment bank failures, tight credit, and the global
economic downturn pushed the United States into a recession by mid-2008. GDP
contracted until the third quarter of 2009, making this the deepest and longest
downturn since the Great Depression. To help stabilize financial markets, in
October 2008 the US Congress established a $700 billion Troubled Asset Relief
Program (TARP). The government used some of these funds to purchase equity in
US banks and industrial corporations, much of which had been returned to the
government by early 2011. In January 2009 the US Congress passed and President
Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus
to be used over 10 years - two-thirds on additional spending and one-third on
tax cuts - to create jobs and to help the economy recover. In 2010 and 2011,
the federal budget deficit reached nearly 9% of GDP. In 2012 the federal
government reduced the growth of spending and the deficit shrank to 7.6% of
GDP. Wars in Iraq and Afghanistan required major shifts in national resources
from civilian to military purposes and contributed to the growth of the budget
deficit and public debt. Through 2011, the direct costs of the wars totaled
nearly $900 billion, according to US government figures. US revenues from taxes
and other sources are lower, as a percentage of GDP, than those of most other
countries. In March 2010, President OBAMA signed into law the Patient
Protection and Affordable Care Act, a health insurance reform that will extend
coverage to an additional 32 million American citizens by 2016, through private
health insurance for the general population and Medicaid for the impoverished.
Total spending on health care - public plus private - rose from 9.0% of GDP in
1980 to 17.9% in 2010. In July 2010, the president signed the DODD-FRANK Wall
Street Reform and Consumer Protection Act, a law designed to promote financial
stability by protecting consumers from financial abuses, ending taxpayer
bailouts of financial firms, dealing with troubled banks that are "too big
to fail," and improving accountability and transparency in the financial
system - in particular, by requiring certain financial derivatives to be traded
in markets that are subject to government regulation and oversight. In December
2012, the Federal Reserve Board announced plans to purchase $85 billion per
month of mortgage-backed and Treasury securities in an effort to hold down
long-term interest rates, and to keep short term rates near zero until
unemployment drops to 6.5% from the December rate of 7.8%, or until inflation
rises above 2.5%. Long-term problems include stagnation of wages for
lower-income families, inadequate investment in deteriorating infrastructure,
rapidly rising medical and pension costs of an aging population, energy
shortages, and sizable current account and budget deficits - including
significant budget shortages for state governments.
|
Source : CIA |
Company name: BRUKER DALTONICS INC.
Address: 40 Manning Road,
Billerica, MA 01821 - USA
Telephone: +1
978-663-3660
Fax: +1 978-667-5993
Website: www.bruker.com
Corporate ID#: 3156683
State: Delaware
Judicial form: Corporation
– Profit
Date incorporated: February
4, 2000
Stock: 1,000
shares common
Value: USD
0.01= par value
Name of manager: Frank
H. LAUKIEN
Business:
Bruker Daltonics Inc. designs, manufactures, and markets life sciences
tools based on mass spectrometry.
It offers matrix assisted laser desorption ionization time of flight
mass spectrometer, electro spray ionization ion trap mass spectrometer, ultra
high resolution time of flight mass spectrometer, fourier transform mass
spectrometer, and mobile detection products. The company also provides systems
for substance detection and pathogen detection for security, defense, and
anti-terrorism applications. It serves pharmaceutical, biotechnology,
proteomics and molecular diagnostics companies, academic institutions, and
government agencies.
Bruker Daltonics Inc. operates as a subsidiary of Bruker Corporation.
Last news :
On April 27, 2013, GeneOhm Sciences Canada Inc. announced an international
distributor agreement with Bruker Daltonics Inc. to sell and provide front-line
technical support for the co-labeled BD(TM) Bruker MALDI Biotyper(TM) System.
Microbial identification and antimicrobial susceptibility testing is the
end-point of the majority of work a microbiology lab performs on a daily basis
and is very time consuming. The BD(TM) Bruker MALDI Biotyper(TM) System
combined with automated antimicrobial susceptibility testing on the BD
Phoenix(TM) Microbiology System and the BD EpiCenter(TM) Microbiology Data
Management System, will facilitate a fully integrated, optimized approach for
laboratory workflow. Antimicrobial susceptibility testing is conducted via
traditional automated systems such as the BD Phoenix System. The combination of
these two proven technologies, the BD Phoenix System and the Bruker MALDI
Biotyper, and data management through the BD EpiCenter System, will provide
laboratorians with a new approach to identification and susceptibility testing,
which is expected to reduce the turnaround time for critical diagnostic
results, while also improving laboratory efficiency and costs. Identification
of pathogens will occur in minutes versus hours -- directly impacting patient
management. The Bruker MALDI Biotyper is currently not available in the United
States for in vitro diagnostic use
Biodesix Announces Agreement with Bruker Daltonics to Support Mass
Spectrometry-based Diagnostic Tests
On April 11, 2013, Biodesix, Inc. announced a collaborative agreement
with Bruker Daltonics Inc. to support Biodesix' VeriStrat diagnostic test as
well as future diagnostic tests based on matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. VeriStrat
is a novel, multivariate serum protein test that helps oncologists personalize
therapy for patients with lung cancer. The new collaboration advances the
companies' existing relationship concerning use of Bruker's MALDI-TOF
instruments with VeriStrat and Biodesix' other clinical diagnostics in
development. The agreement provides avenues for valuable hardware and
software/applications support as well as access to the latest in instrument
designs and improvements. MALDI-TOF mass spectrometry is a powerful analytical
platform that can provide detailed and discriminating information about complex
biological samples, but with relatively simple sample preparation and high
throughput. The combination of Biodesix' platform technology, including
Biodesix' sophisticated and proprietary data analysis algorithms, and Bruker instruments,
valued for their outstanding performance, reliability, and innovative designs
forms the basis for a robust clinical diagnostics platform.
Suppliers include:
MAGNEX SCIENTIFIC LIMITED
6 MEAD ROAD, OXFORD IND ESTATE YARNTON OXFORD OX5 1QU UK
BRUKER DALTONICS K.K.
21-5, NINOMIYA 3-CHOME TSUKUBA-CITY IBARAKI JAPAN
EIN: -
Staff: 600
Operations & branches:
At the headquarters, we
find a large factory, warehouse and office.
The Company maintains a sales office located:
3500 West Warren Avenue
Fremont, CA 94538
Ph: +1 510-683-4300
Shareholders:
BRUKER CORP.
40 Manning Road, Billerica, MA 01821
The Company is listed with the Nasdaq under
symbol BRKR.
Bruker Corporation, together with its
subsidiaries, engages in the design, manufacture, sale, and service of
proprietary life science and materials research systems, and associated
products worldwide.
Management:
Frank H. LAUKIEN, President, Director and CEO
He has been the Chairman, Chief Executive Officer and President of
Bruker Corporation of Bruker BioSpin GmbH and Bruker Optics Inc. since February
1991. Dr. Laukien has been the Chairman of the Board, President and Chief
Executive Officer of Bruker Daltonics Inc. since February 1991. Dr. Laukien
serves as Chief Executive Officer and President of Bruker BioSciences. Dr.
Laukien has been the President of Bruker BioSpin Corporation, an affiliate of
Bruker BioSciences, since June 1997 and serves as its Co-Chief Executive
Officer.
He has been the Co-Chief Executive Officer of the worldwide Bruker
BioSpin family of companies since December 2002. Dr. Laukien served as the
Chief Executive Officer of Bruker AXS Inc. from October 1997 to March 2000 and
its Executive Chairman from October 1997 to July 2003. Dr. Laukien has been a
Director of Bruker BioSciences Corp. since June 1997. He has been Director of
Bruker Energy & Supercon Technologies, Inc. since April 2008.
He has been Director of Bruker BioSpin Corporation since June 1997.
He served as a Director at Bruker AXS Inc. from October 1997 to March
2000.
A part-time professor of mass spectrometry at the University of
Amsterdam, Dr. Laukien holds a B.S. from the Massachusetts Institute of
Technology and a Ph.D. in chemical physics from Harvard University.
In November 2001, he was elected an officer and Chairman- Elect of ALSSA
(Analytical & Life Science Systems Association), an industry organization.
Stefan RUGE, CFO
Subsidiaries:
|
Bruker Daltonik GmbH |
|
Germany |
|
Bruker s.r.o. |
|
Czech Republic |
|
Bruker Saxonia Mechanik GmbH |
|
Germany |
|
Bruker Daltonics India Pvt. Ltd. |
|
India |
|
Bruker BioSciences Korea Co., Ltd. |
|
South Korea |
|
Bruker Taiwan Co. Ltd. |
|
Taiwan |
|
Bruker Daltonics K.K. |
|
Japan |
|
Bruker Daltonics Pte. Ltd. |
|
Singapore |
|
Bruker Daltonics Pty. Ltd. |
|
South Africa |
|
Bruker Daltonics Scandinavia AB |
|
Sweden |
|
Bruker Chemical Analysis B.V. |
|
Netherlands |
|
Bruker BioSciences Pty. Ltd. |
|
Australia |
|
Bruker Daltonics GmbH |
|
Switzerland |
|
Bruker Daltonics Ltd. |
|
United Kingdom |
|
Bruker Daltonics S.r.l. |
|
Italy |
|
Bruker Daltonique S.A. |
|
France |
|
Bruker Panama S. de R.L. |
|
Panama |
In United States, privately held corporations are not required to
publish any financials.
On a direct call, a financial assistant controlled the present report
and confirmed that all financials are consolidated into the parent company
which reported the following:
|
Currency in |
|
Dec 31 |
Dec 31 |
Dec 31 |
Dec 31 |
|
TOTAL REVENUES |
1,114.5 |
1,304.9 |
1,651.7 |
1,791.4 |
|
|
NET INCOME |
81.2 |
95.4 |
92.3 |
77.5 |
|
However, estimate sales for
BRUKER DALTONICS INC. is in the range of
USD 70,000,000=
Banks: JPMorgan Chase Bank
Legal filings
& complaints:
As of today date, there is no legal filing pending with the Courts.
Secured debts summary (UCC):
None (in Massachusetts)